The features that matter for a software company, such as deal velocity, email volume, and a fast pipeline, are not the ones that matter when you sell reagents, kits, or instruments through distributors and direct into labs across a multi-year cycle. Below are the factors that actually separate a CRM built for life science commercialization from one that just stores contacts.
| QUICK ANSWER
The key factors in choosing a biotech CRM are whether it can run direct and distributor sales in one pipeline, model long scientific sales cycles, capture the scientific data that qualifies a life science buyer, track samples and evaluations, give you channel visibility, unify marketing and sales, support AI on approved data, integrate with your existing stack, and connect activity to revenue. Evaluate the platform based on its fit for life science workflows, not generic B2B feature counts. |
1. Can the CRM run direct and distributor sales in one system?
| DIRECT ANSWER
The most important factor for most biotech companies is whether the CRM can manage direct sales and distributor (channel) sales in one system so leads, quotes, and revenue are visible whether a deal closes in-house or through a partner, instead of splitting your commercial picture across disconnected spreadsheets. |
Most life science product companies sell through a mix of direct sales and regional or specialist distributors. A CRM that only models direct selling quietly forces all channel activity into spreadsheets. With them goes any real view of pipeline, follow-up, or revenue by partner. When you evaluate a platform, look for:
The ability to route leads to distributors and track what happens next
Shared target lists and account assignments across direct and channel teams
Deal and revenue attribution by channel
Record types or associations that model partners, not just customers
2. Does it model long, scientific sales cycles, not just fast transactions?
| DIRECT ANSWER
A biotech CRM must be able to model long, nonlinear sales cycles, often 12 to 36 months and tied to grants and program budgets, with customizable lifecycle stages and an evaluation step, because a CRM built to push deals to close in 30 days will consistently misrepresent your pipeline. |
Life science purchases track to funding timelines and program milestones, not a monthly sales sprint. The CRM should let you:
Customize lifecycle and deal stages to match your real journey
Add an explicit sample or evaluation stage where deals are actually decided
Set stage SLAs so long-cycle leads don’t quietly stall
Forecast in a way that tolerates multi-quarter cycles
| Evaluating CRMs and want one already shaped for life science cycles?
PSG Life Sciences is a HubSpot Gold partner that configures the platform specifically for biotech sales cycles, evaluation stages, sample tracking, and distributor pipelines built in from day one. |
3. Can it capture the scientific data that qualifies a life science buyer?
| DIRECT ANSWER
Evaluate whether the CRM lets you capture the scientific context that actually qualifies a life science buyer, including application, sample type, platform, throughput, and funding, through custom properties and, ideally, custom objects, rather than forcing scientific data into generic firmographic fields. |
In life science markets, fit is scientific before it is commercial. The CRM’s data model determines whether a rep can look at a record and know if it’s worth pursuing. Look for flexible custom properties and, on higher tiers, custom objects to model products, instruments, or distributors as first-class records. If the platform can only store company size and industry, it can’t qualify your buyers.
4. Does it treat sample requests and evaluations as tracked events?
| DIRECT ANSWER
Because sample requests and evaluations are where life science deals are won or lost, a strong biotech CRM treats them as tracked commercial events with intake, ownership, follow-up, and conversion tracking rather than as informal giveaways that disappear the moment they ship. |
The evaluation stage is the single most under-managed part of most life science pipelines. A capable CRM supports:
A structured sample-request intake workflow
Automatic tasks to sales and technical support
Evaluation outcome tracking and conversion to a quote
Visibility into how many samples convert, by application
5. Does it give you real distributor visibility and accountability?
| DIRECT ANSWER
For companies that sell through channels, a critical factor is whether the CRM delivers distributor accountability, including shared target lists, tracking of leads sent and followed up, and pipeline by distributor, since passive channel relationships rarely scale revenue without that visibility. |
Handing leads to a distributor and hoping is not a channel strategy. The CRM should let you track leads sent, follow-up status, quotes generated, revenue closed, and pipeline by partner, turning distributor relationships from a black box into a managed, measurable part of the business.
| Distributor pipeline feel like a black box?
PSG helps growth-stage life science companies build distributor accountability, shared target lists, and CRM visibility into channel performance. |
6. Are marketing and sales unified in one platform?
| DIRECT ANSWER
Choose a CRM where marketing and sales live in one platform, so demand generation, website behavior, lead scoring, and pipeline connect from end to end. Fragmenting them across disconnected tools is the most common reason life science commercial data never adds up. |
When forms, email, campaigns, website intent, and pipeline sit in separate systems, no one can trace a customer from first touch to reorder. A unified platform lets marketing activity flow into qualification and sales without manual stitching. It also lets you finally answer which campaigns and content actually produce revenue.
7. How well does it support AI and automation on approved data?
| DIRECT ANSWER
Assess how the CRM supports AI and automation grounded in approved, validated data for enrichment, scoring, follow-up, and record summaries, since AI that invents scientific or performance claims is a real liability in technical and regulated markets. |
AI is a genuine advantage in commercial execution, but only with guardrails. The right platform lets automation and AI draw on your CRM data and approved company knowledge, including application notes, validated claims, and product information, rather than generating unsupported scientific or regulatory statements. Evaluate the guardrails as carefully as the capabilities.
8. Does it integrate with your existing commercial and lab stack?
| DIRECT ANSWER
A biotech CRM should integrate cleanly with the systems around it, including ERP, quoting or e-commerce, and marketing tools, so orders, quotes, and customer activity flow without the manual re-entry that quietly erodes data quality. |
A CRM that can’t talk to the rest of your stack becomes another silo. Check for native integrations or a robust API to connect ordering, quoting, e-commerce, and finance systems, so the CRM reflects real commercial reality instead of a partial, hand-typed copy of it.
9. Does the reporting connect activity to revenue?
| DIRECT ANSWER
The reporting factor comes down to whether the CRM connects commercial activity to revenue by product family, application, lead source, and channel because dashboards that count activity without tying it to revenue can’t tell a commercial leader where to invest. |
The metrics that guide a biotech commercial leader are revenue by product family and segment, lead source to revenue, quote-to-order conversion, and distributor conversion. If a platform can show you activity but not its revenue outcome, it will keep you busy without making you smarter.
10. Will your team actually use it?
| DIRECT ANSWER
Finally, weigh whether your team will actually use the CRM day to day, the best-fit platform is the one that gets adopted, so factor in implementation effort, tier cost, and whether you have the expertise to configure it for life science workflows, not just its feature list. |
The most powerful CRM is worthless if reps route around it. Adoption depends less on features than on how well the system is configured for the way your team actually sells, which is why the implementation partner often matters more than the platform choice. Weigh the real cost of the right tier, and be honest about whether you have the expertise in-house to set it up for a life science commercial model.
| Have the right CRM but no one to configure it for how you sell?
PSG provides fractional commercial leadership with senior sales and marketing expertise, without the cost or risk of a full-time hire, to select, implement, and operationalize the CRM around your commercial model. |
Bottom Line: Which CRM best fits these factors for a biotech company?
| DIRECT ANSWER
For most biotech product companies, HubSpot fits these factors best, unifying direct and distributor sales, marketing, and revenue reporting in one platform, but the deciding factor is configuration: any CRM only supports life science commercialization when it is set up around how scientific customers evaluate, buy, and reorder. |
No CRM is “the biotech CRM” out of the box. The platform that wins is the one that can be shaped to run direct and distributor sales together, model a long scientific cycle, capture scientific qualification data, and tie every activity back to revenue, and that your team will actually adopt. Evaluate for that fit, then invest in the configuration that makes it real. That is where a generic contact database becomes a commercial operating system.
| Ready to choose and configure the right CRM for your commercial model?
Talk to PSG Life Sciences about evaluating and implementing a CRM built for biotech, including direct and distributor sales, scientific qualification, sample tracking, and revenue reporting. |